Escalon Medical Corp FY 2026: Revenue $12.74M, EPS $0.27— 10-K Summary
Escalon Medical Corp reported FY 2026 revenue of $12.74M, up 5.7% YoY, and net income of $4.01M, driven by Sonomed sales and a one-time gain from AXIS software sale. International sales rose to 46.4% of revenue. R&D spending declined 33.5%.
How this was made

The 30-second read
Why it matters
The earnings beat and software sale provide a short‑term catalyst, but the small scale limits broader market impact.
Market read
Primary earnings disclosure for a micro‑cap; modest upside potential for the stock.
What to watch
Decline in Trek and AXIS product sales could signal longer‑term product mix challenges.
Background
Escalon Medical Corp is a micro‑cap medical device company reporting its FY 2026 results via a 10‑K filing.
Ticker impact
Escalon Medical Corp disclosed FY 2026 results with $12.74M revenue and $4.01M net income, a 5.7% revenue increase and a 3702.5% EPS jump.
likely modest upside as the market prices in the earnings beat and one‑time software sale gain
Earnings beat and a sizable one‑time gain are new information, but the absolute dollar size is small for a micro‑cap, limiting the move.
Market effects
Shows modest growth in niche medical device segment; may prompt peers to highlight similar product lines.
International sales now 46% of revenue, indicating expanding overseas exposure.
Limited; impact confined to small‑cap medical device space.
Counterpoint
The one‑time software sale inflates earnings; future quarters may revert to lower profitability.
Key entities
- companyEscalon Medical Corp
Medical device manufacturer reporting FY 2026 results.
